This article will be permanently flagged as inappropriate and made unaccessible to everyone. Are you certain this article is inappropriate? Excessive Violence Sexual Content Political / Social
Email Address:
Article Id: WHEBN0016115433 Reproduction Date:
4-fluoro-N-[3-(1-methyl-4-piperidinyl)-1H-indol-5-yl]benzamide
LY-334,370
CN1CCC(c2c3cc(N([H])C(c4ccc(F)cc4)=O)ccc3n([H])c2)CC1
LY-334,370 is a selective 5-HT1F receptor agonist[1] which was under development by Eli Lilly and Company for the treatment of migraine headaches.[2] The drug showed efficacy in a phase II clinical trial[3] but further development was halted due to toxicity detected in animals.[4]
Serotonin, Ergoline, Methysergide, 5-Carboxamidotryptamine, Asenapine
Serotonin, Ergoline, Lysergic acid diethylamide, 5-Methoxytryptamine, Methysergide